A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.

Summary

This 2 arm study will evaluate the management of Tarceva-induced skin rash in patients with non-small cell lung cancer who have failed first-line chemotherapy for advanced disease. Eligible patients will be randomized to receive a)doxycycline 100mg po daily or b)no preventative treatment; all patients will receive Tarceva 150mg/kg po daily. The anticipated time on study treatment is until disease progression or intolerable toxicity, and the target sample size is 100-500 individuals.

Timeline

Start

2007-10

Primary completion

2010-08

Completion

2010-08

Drugs

Indications